Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects (PRIOH-1)
HSV Infection
About this trial
This is an interventional treatment trial for HSV Infection
Eligibility Criteria
Part C inclusion criteria
Immunocompromised men and women of any ethnic group aged ≥16 years.
In Canada, Germany, Belgium:
Immunocompromised (due to conditions including HIV infection, hematopoietic cell or solid organ transplantation, and chronic glucocorticoid use) men and women of any ethnic group aged >18 years.
- ACV-R mucocutaneous HSV infection based on clinical failure, requiring switch to foscarnet treatment or positive genotypic/phenotypic ACV resistance testing for current lesion. Clinical failure is defined as no improvement after oral or iv doses for at least 7 days withat doses equivalent to or greater than the local agency approved high oral doses withof acyclovir, (800 mg TID) or valacyclovir or famciclovir.(1 g TID).
- Lesions accessible for visual inspection to allow assessment of lesion healing including visualization by endoscopy or pharyngoscopy.
- Willingness to abstain from the application of lotions and/or creams to the area with HSV lesions. Wet/dry saline dressings or bandages at lesion site are allowed.
- Willingness to use highly effective birth control.
- Subject, and/or their legally authorized representative, (proxy consent is not permitted in Germany), must be willing and able to understand the Informed Consent Form.
- Negative serum β-HCG (beta-human chorionic gonadotropin) test for women of child-bearing potential at Screening and a negative urine pregnancy test at Day 1.
- Written informed consent. For subjects, who are unable to provide informed consent for whatever reason, written consent must be obtained from the legal representative, (proxy consent is not permitted in Germany).
Part D and F inclusion criteria
All inclusion criteria as for Part C, except for inclusion criterion 2, which is replaced by:
2. ACV-R and foscarnet-R mucocutaneous HSV infection based on clinical failure or positive genotypic/phenotypic resistance testing for current lesion or documented intolerance to iv foscarnet requiring cessation of foscarnet treatment or precluding foscarnet treatment.
Subjects will be able to enter Part F only after closure of enrollment in Part D.
Part E inclusion (Part E is not being conducted in Germany)
All inclusion criteria as for Part C, except for inclusion criterion 2, which is replaced by:
2. Recurrent mucocutaneous HSV infection considered ACV-S.
Part C exclusion criteria
- Known resistance/intolerance to pritelivir and/or foscarnet or any of the excipients.
- Previous treatment in PRIOH-1.
- Need to use paclitaxel.
- Baseline safety laboratory abnormalities.
- History or current evidence of gastrointestinal malabsorption which, in the opinion of the Investigator, may affect the extent of absorption of pritelivir.
- Severe renal insufficiency (eGFR ≤29 mL/min/1.73 m2).
- History or current evidence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, hematological, endocrinological, metabolic, neurological, psychiatric, or other relevant diseases.
- Abnormalities in hematological, clinical chemical or any other laboratory variables.
- Not able to communicate meaningfully with the Investigator and site staff.
- Any other condition which in the opinion of the Investigator would interfere with successful completion of this clinical trial.
- Any other important local condition.
- Pregnant and/or breastfeeding women.
- Having received an investigational drug in an investigational drug trial unter certain conditions.
Part D exclusion criteria
All exclusion criteria as for Part C, except for exclusion criterion 1, which is replaced by: 1. Known intolerance to pritelivir or any of the excipients and except criterion 13, which is replaced by: 13. Having received an investigational drug in an investigational drug within 7 half-lives after the last administration of this drug before initiating trial medication, except for subjects entering Part D, who have previously received foscarnet treatment in Part C of this trial.
Participation in a clinical trial without receiving other investigational drugs (eg, follow-up phase of a trial, observational study) is permitted.
Part E exclusion criteria (Part E is not being conducted in Germany)
All exclusion criteria as for Part C, except for exclusion criteria 1, which is replaced by
1. known intolerance to pritelivir or any of the excipients and addition of 14. Having used (val)acyclovir within 3 days prior to starting pritelivir.
Part F exclusion criteria All exclusion criteria for Part D plus 14. Part D open for enrollment
Sites / Locations
- University of Alabama at BirminghamRecruiting
- University Arizona - Department of Medicine Arizona Health Sciences CenterRecruiting
- City of HopeRecruiting
- Cedars-Sinai Medical CenterRecruiting
- University of California, Division of Infectious DiseasesRecruiting
- IMMUNOe International Research Centers
- Yale University School of Medicine - Infectious DiseasesRecruiting
- Midland Florida Clinical Research Center, LLCRecruiting
- Midway Immunology and Research Center (MIRC)Recruiting
- University of Florida (UF) - Division of Infectious DiseaseRecruiting
- Palmetto Professional ResearchRecruiting
- Links Clinical TrialsRecruiting
- Emory Hospital Midtown Infectious Disease ClinicRecruiting
- Department of Medicine J. H. Stroger Hospital of Cook CountyRecruiting
- LSU Health Baton Rouge Pulmonary ClinicRecruiting
- Johns Hopkins University School of MedicineRecruiting
- Massachusetts General HospitalRecruiting
- Brigham and Women's HospitalRecruiting
- Wayne State University
- University of Nebraska Medical CenterRecruiting
- David H. Koch Center at Memorial Sloan Kettering Cancer CenterRecruiting
- Atrium Health Wake Forest BaptistRecruiting
- Cincinnati Children's Hospital Medical CenterRecruiting
- University of Pittsburgh Medical CenterRecruiting
- MD Anderson Cancer CenterRecruiting
- Fred Hutchinson Cancer Research CenterRecruiting
- Hospital RawsonRecruiting
- Sanatorio Mayo Privado S.A.Recruiting
- Instituto FIDESRecruiting
- Melbourne Health - Royal Melbourne HospitalRecruiting
- Westmead Hospital, Centre for Infectious Disease and MicrobiologyRecruiting
- Centre Hospitalier Universitaire Saint PierreRecruiting
- AZ DeltaRecruiting
- Alberta Health Services Cross Cancer Institute at the University of AlbertaRecruiting
- Beijing Ditan Hospital Capital Medical University
- CHU Limoges - Centre national de reference des Herpes virusRecruiting
- CHU de NantesRecruiting
- Hôpital Saint Louis - AP-HPRecruiting
- AP-HP Hopital Necker-Enfants MaladesRecruiting
- AP-HP Hopital Bichat - Claude BernardRecruiting
- LLC DiakorRecruiting
- JSC CuratioRecruiting
- Multiprofile Clinic Consilium Medulla LTDRecruiting
- Universitätsklinikum KölnRecruiting
- Muenchen Klinik NeuperlachRecruiting
- General Hospital of Athens - LaikoRecruiting
- Regional University General Hospital of HeraklionRecruiting
- Chaim Sheba Medical CenterRecruiting
- Grande Ospedale Metropolitano "Bianchi Melacrino Morelli"Recruiting
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MilanoRecruiting
- Fondazione IRCCS Policlinico San MatteoRecruiting
- Centro de Investigacion Clinica GRAMEL S.C.Recruiting
- Instituto de Investigaciones Aplicadas a la Neurociencia A.CRecruiting
- Centro de Investigacion Farmaceutica Especializado de Occidente S.C.Recruiting
- Unidad de Investigacion CIMA SCRecruiting
- Clinical Research Institute Saltillo S.A de C.V
- Arke SMO S.A. de C.V.Recruiting
- Universitaetsspital Basel Ambulantes Studienzentrum
- Hopitaux universitaires de GeneveRecruiting
- Universitaetsspital ZuerichRecruiting
- Chelsea and Westminster HospitalRecruiting
- Research Department of Haematology, UCL Cancer InstituteRecruiting
- Freeman HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Experimental
Active Comparator
Experimental
Experimental
Experimental
Part C, Pritelivir
Part C, Foscarnet
Part D, Pritelivir
Part E, Pritelivir
Part F, Pritelivir
Oral tablets, 100mg/day (400mg loading dose on day 1) for up to 28 days and potential prolongation for up to additional 14 days
iv solution, 40 mg/kg tid or 60mg/kg bid for up to 28 days and potential prolongation for up to additional 14 days.
Oral tablets, 100mg/day (400mg loading dose on day 1) for up to 28 days and potential prolongation for up to additional 14 days
Oral tablets, 100mg/day (400mg loading dose on day 1) for up to 28 days and potential prolongation for up to additional 14 days
Oral tablets, 100mg/day (400mg loading dose on day 1) for up to 28 days and potential prolongation for up to additional 14 days